Ozmosi | PIN-5018 Drug Profile
Drug Profile
Using advanced filters...

PIN-5018

Alternative Names: PIN-5018, PIN5018, PIN 5018
Clinical Status: Active
Latest Update: 2025-11-24
Latest Update Note: News Article

Product Description

PIN-5018 is an oral (ingredient-based) p53 degrader developed based on the "synthetic activation of p53" hypothesis. It is currently being pursued as a monotherapy and in various combination strategies. This phase 1 clinical trial will evaluate safety, pharmacokinetics (PK), target binding and pharmacologic activity (engagement) of the CK1α degrader through dose escalation. The company plans to expand the scope of development to include Merkel cell carcinoma, neuroblastoma, acute myeloid leukemia (AML), and high-risk myelodysplastic syndromes (HR-MDS). (Sourced from: https://www.thebionews.net/news/articleView.html?idxno=20041)

Mechanisms of Action: CK1a Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Pin Therapeutics
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Adenoid Cystic Carcinoma|Acute Myeloid Leukemia|Prostate Cancer|Colorectal Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events